| Joshua William Balts, | |
|
1222 E Woodland Ave, Barron, WI 54812-1765 | |
| (715) 537-3186 | |
| Not Available |
| Full Name | Joshua William Balts |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 12 Years |
| Location | 1222 E Woodland Ave, Barron, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104184092 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 61103-20 (Wisconsin) | Secondary |
| 207X00000X | Orthopaedic Surgery | 61103 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System-northland | Barron, WI | Hospital |
| Mayo Clinic Health System Eau Claire Hospital | Eau claire, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-northwest Wisconsin Region Inc | 4385553627 | 623 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1154372944 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000001 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740239557 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000112 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1912958026 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000215 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700837812 PECOS PAC ID: 4385553627 Enrollment ID: O20171012001230 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua William Balts, Po Box 1510, Eau Claire, WI 54702-1510 Ph: (715) 838-5222 | Joshua William Balts, 1222 E Woodland Ave, Barron, WI 54812-1765 Ph: (715) 537-3186 |
News Archive
Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.
Tulane University's Stryder Meadows, a cell and molecular biology professor, received a $1.7 million grant from the Department of Defense to study how arteriovenous malformations (AVM), which are defects in arteries, veins and capillaries, form Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that affects about 1 in 5,000 people.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
› Verified 5 days ago
James R Leavitt, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1222 E Woodland Ave, Barron, WI 54812 Phone: 715-537-3166 |